— Know what they know.
Not Investment Advice
Also trades as: PFE.TO (TSX) · $vol 1M · PFE.F (FSX) · $vol 1M · PFE.DE (XETRA) · $vol 1M · PFE.NE (NEO) · $vol 1M · PFE.BA (BUE) · $vol 0M

PFE NYSE

Pfizer Inc.
1W: +1.2% 1M: +3.9% 3M: +18.0% YTD: +20.3% 1Y: +22.9% 3Y: +10.2% 5Y: -10.7%
$29.80
+0.01 (+0.03%)
After Hours: $29.77 (-0.03, -0.10%)
Weekly Expected Move ±2.9%
$28 $29 $30 $31 $32
NYSE · Healthcare · Drug Manufacturers - General · Tech Score Strong Buy · Power 73 · $169.8B mcap · 5.69B float · 0.677% daily turnover · Short 44% of daily vol
Credit Risk of going bust: lower than 82% of companies Debt: 27.1% of company value Bonds: $1.15B held by 485 funds, 62 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.54 (down 98%), Pfizer Inc. would be worth roughly what it owes.
Total debt $63.19B against a stock market value of $169.79B.
Distance to default 10.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $32.95B (short-term plus half of long-term), stock volatility 21.2%; Altman Z 2.14. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Smart Money Score
Bullish 100
Insider+$3.0M
Congress3 trades
ETF Holdings—
Key Statistics
Market Cap$169.8B
52W Range23.62-30.44
Volume25,278,348
Avg Volume38,551,658
Beta0.28
Dividend$1.72
Analyst Ratings
16 Buy 23 Hold 1 Sell
Consensus Hold
Company Info
CEOAlbert Bourla
Employees75,000
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date1972-06-01
Websitepfizer.com
66 Hudson Boulevard East
New York City, NY 10001-2192
US
212 733 2323
About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Recent Insider Trades

NameTypeSharesPriceDate
BOURLA ALBERT A-Award 20 — 2026-10-15
BOURLA ALBERT A-Award 71 — 2026-10-13
BOURLA ALBERT A-Award 21 — 2026-09-30
Buckley Mortimer J A-Award 1,308 — 2026-09-25
Echevarria Joseph A-Award 1,613 — 2026-09-25

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms